This research develops orally administered nanoparticles that target the lymphatic system to treat lupus and osteoporosis simultaneously. By delivering drugs directly to affected tissues while avoiding the bloodstream, the approach reduces toxicity, suppresses inflammatory and bone-damaging genes, and offers a more effective strategy for treating these complex chronic diseases.

This research investigates the safety of targeted synthetic DMARDs during pregnancy in people with autoimmune joint diseases. Using 20 years of population-level health data, it identifies increased risk of low birth weight associated with prenatal exposure. The findings aim to inform clinical guidance and empower patients to make safer, evidence-based decisions about pregnancy.